Japan Authorities Authorize Sanofi, Regeneron's Praluent
July 05 2016 - 2:18AM
Dow Jones News
By William Horobin
PARIS--France's Sanofi SA (SAN.FR) and U.S. biopharma company
Regeneron Pharmaceuticals Inc. (REGN) said Tuesday that Japanese
authorities have authorized the drug companies' cholesterol
treatment Praluent.
Praluent has already been approved in the U.S., the European
Union, Canada and Mexico. In Japan, ministry of health, labor and
welfare granted marketing and manufacturing authorization for
Praluent for the treatment of patients with hypercholesterolemia
and familial hypercholesterolemia in whom treatment with statins
isn't sufficient.
"Hypercholesterolemia is a significant concern in Japan," said
Jay Edelberg, Head of Cardiovascular Development at Sanofi.
-Write to William Horobin at william.horobin@wsj.com
(END) Dow Jones Newswires
July 05, 2016 02:03 ET (06:03 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024
